Cytokines in Sjogren's syndrome: potential therapeutic targets.
about
Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis.Effect of mesenchymal stem cells on Sjögren-like mice and the microRNA expression profiles of splenic CD4+ T cellsProteomic analysis of saliva: a unique tool to distinguish primary Sjögren's syndrome from secondary Sjögren's syndrome and other sicca syndromesGenetics and genomics of Sjögren's syndrome: research provides clues to pathogenesis and novel therapies.Innate immune signaling induces interleukin-7 production from salivary gland cells and accelerates the development of primary Sjögren's syndrome in a mouse modelGenetic and pharmacologic inhibition of the Ca2+ influx channel TRPC3 protects secretory epithelia from Ca2+-dependent toxicity.Upregulation of NLRP3 Inflammasome in the Tears and Ocular Surface of Dry Eye Patients.Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sjögren's syndromeTACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice.Frankincense and myrrh suppress inflammation via regulation of the metabolic profiling and the MAPK signaling pathwaySignificance of Interleukin-6/STAT Pathway for the Gene Expression of REG Iα, a New Autoantigen in Sjögren's Syndrome Patients, in Salivary Duct Epithelial Cells.Serum interleukin-17 & nitric oxide levels in patients with primary Sjögren's syndrome.Interleukin-6 inhibits apoptosis of exocrine gland tissues under inflammatory conditionsT Cell-Associated Cytokines in the Pathogenesis of Sjögren's SyndromeEffect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study.Interleukin-7 enhances the Th1 response to promote the development of Sjögren's syndrome-like autoimmune exocrinopathy in miceEndogenous programmed death ligand-1 restrains the development and onset of Sjӧgren's syndrome in non-obese diabetic mice.Smad4 in T cells plays a protective role in the development of autoimmune Sjögren's syndrome in the nonobese diabetic mouse.Pathogenic role of endogenous TNF-α in the development of Sjögren's-like sialadenitis and secretory dysfunction in non-obese diabetic mice.Biological therapies in primary Sjögren's syndrome.Biologics in oral medicine: Sjogren syndrome.Biologic treatment in Sjögren's syndrome.Evaluation of chemical constituents and important mechanism of pharmacological biology in dendrobium plants.Polysaccharides of Dendrobium officinale inhibit TNF-α-induced apoptosis in A-253 cell line.Use of biologic agents in ocular manifestations of rheumatic disease.Effect of Systemic Infliximab Therapy in Patients with Sjögren's Syndrome.P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy.Interleukin-6/STAT pathway is responsible for the induction of gene expression of REG Iα, a new auto-antigen in Sjögren׳s syndrome patients, in salivary duct epithelial cells.Correlation of interleukin-33 with Th cytokines and clinical severity of dry eye disease.Cholinergic anti-inflammatory pathway in the non-obese diabetic mouse model.Sjögren-Like Lacrimal Keratoconjunctivitis in Germ-Free Mice.Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18.Rotavirus intestinal infection induces an oral mucosa cytokine response.Co-culture system of human salivary gland epithelial cells and immune cells from primary Sjögren's syndrome patients: an in vitro approach to study the effects of Rituximab on the activation of the Raf-1/ERK1/2 pathway.Elevated level of circulating CD4+Helios+FoxP3+ cells in primary Sjogren's syndrome patients.IL-17A and IL-17F polymorphisms in rheumatoid arthritis and Sjögren’s syndrome
P2860
Q33667694-E3D1262C-8F25-46C1-8660-34C02E78E372Q33744508-491F0272-A160-4F65-9FB0-2CCD92E94B90Q34083843-C0D93DFE-0316-4C03-B118-46EBA986DF77Q34984739-E45D313A-A39B-49CC-BBF3-394A00ACD2CDQ35023259-46247BD5-78DB-4EFD-B2D4-0BA63361F6E1Q35028058-59309DCB-DE99-4357-BB8E-3116844A269DQ35592392-8816B8E6-B124-4F93-9F92-B15BC972B951Q35676007-D7367C75-021C-4016-B890-65721C06A71DQ35857131-7DAD82C5-3D34-48F6-A389-FB05258410F5Q36017886-27DB9FA1-B671-49F7-8DA7-6C9FF42B5B63Q36060629-9E03029D-BEFB-4D6A-9E33-F963849D0E2FQ36064302-5D6F670E-04A8-4FB8-AD76-B523DE9BB2CEQ36161896-9FCCC3E3-09FE-4D43-A345-28CDCAA360A7Q36957148-B3E32F36-9A0A-4848-9C95-53E9A9558BBBQ36989837-534607CD-0FBA-47AF-9398-E4EDBFBC635CQ37060371-79A50C3C-99DE-43C3-8952-71D23E762181Q37501812-76AE8716-FAE4-440F-A183-901B0A337F43Q37696996-BA63B48C-A023-491D-8352-1B26453F1729Q37733323-B1765B51-C820-4F27-A02E-D25020D0F812Q37860347-28DCDA18-39B7-4764-8177-AA57C8D0D1F2Q38002156-F819F39E-5255-4336-BAC8-A763EF092C2BQ38262453-F51C369D-47EB-4571-A763-2B96864FF305Q38461770-F666D6D5-F250-4B75-95E2-A96A129E1531Q39221016-76CA1431-F4AB-487C-8649-25395E0F7D20Q40008319-EBB97A6E-F266-4BC5-AAED-1784B9BA1479Q41592241-8EA643B6-55AF-4736-839D-1A6F682751B4Q46322679-1A6FB26F-567A-447E-93E0-A984963517C5Q46974371-E8663F31-9643-4652-ABDA-7FF5AE260892Q47250165-3F50C9B5-5E72-43E5-AF38-D4473083BD78Q49131251-D204AFDF-6AF5-43D7-8E12-FAD779798244Q50041932-9DBC8473-DA0F-4850-AC8D-F4DB186943A9Q53542274-763C8245-B73F-4995-A8D8-4549D4DD616AQ54241218-BE75556C-BE26-4830-9319-2FFA179498C2Q54310740-47C718D9-6AC5-40FE-83B5-B94229543CA6Q54400978-C3AB0239-CDEA-4474-B2C3-CB3D365DD706Q56786588-ED563D8B-6565-4479-BB9A-4C8A02C07AD7
P2860
Cytokines in Sjogren's syndrome: potential therapeutic targets.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cytokines in Sjogren's syndrome: potential therapeutic targets.
@ast
Cytokines in Sjogren's syndrome: potential therapeutic targets.
@en
Cytokines in Sjogren's syndrome: potential therapeutic targets.
@nl
type
label
Cytokines in Sjogren's syndrome: potential therapeutic targets.
@ast
Cytokines in Sjogren's syndrome: potential therapeutic targets.
@en
Cytokines in Sjogren's syndrome: potential therapeutic targets.
@nl
prefLabel
Cytokines in Sjogren's syndrome: potential therapeutic targets.
@ast
Cytokines in Sjogren's syndrome: potential therapeutic targets.
@en
Cytokines in Sjogren's syndrome: potential therapeutic targets.
@nl
P2093
P2860
P356
P1476
Cytokines in Sjogren's syndrome: potential therapeutic targets.
@en
P2093
Gabor G Illei
Nienke Roescher
Paul P Tak
P2860
P304
P356
10.1136/ARD.2009.115378
P407
P577
2010-04-21T00:00:00Z